The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and increase costs by billions of dollars.
Previous Story
New to the Fed, Miran Defends Calls for Sharper Reduction in Interest Rates
Next Story
Oil Sanctions Have Made Russia’s Shadow Fleet Swell
